Buparlisib (BKM120, NVP-BKM120)

Catalog No.S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 41 Publications

6 Customer Reviews

  • NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.

    Cell, 2017, 161(4):803-16. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017, 16(4):637-648. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MXrDfZRwfG:6aXOgRZN{[Xl? MUO3NkBp M161ZWROW09? MmfTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCHNUS1T{BufXSjboSge4l1cCCJSUWwJI9nKDBwMECwNVU5KM7:TR?= M2r4[FI1QTByMk[2
DU145 M{nrSmN6fG:2b4jpZ{BCe3OjeR?= M1rTU|czKGh? NWP1W4lGTE2VTx?= NU\sb|hWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiZYjwdoV{e2mwZzDMT2IyKG23dHHueEB4cXSqIFfJOVAhd2ZiMD6wNFA1OzVizszN NGjOcYQzPDlyMEK2Oi=>
A2780 MYfDfZRwfG:6aXOgRZN{[Xl? Mln6O|IhcA>? NETaT4dFVVOR M1nCT2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO|gxKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY{PSEQvF2= M2\PNVI1QTByMk[2
U87MG NEPlS4hEgXSxdH;4bYMhSXO|YYm= MorLO|IhcA>? NULTSoFLTE2VTx?= MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCXOEfNS{Bk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2PVgh|ryP NVnNZ2NkOjR7MECyOlY>
A2780 MkW1SpVv[3Srb36gRZN{[Xl? NYKwVnB1OSCq NVrD[FRxTE2VTx?= NVfTNZJZUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlA2PSEQvF2= NHnWbGwzPDlyMEK2Oi=>
DU145 M4TjdWZ2dmO2aX;uJGF{e2G7 Mnn6NUBp M3LTZ2ROW09? MkmyTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1? NEniVoUzPDlyMEK2Oi=>
A2780 MXzGeY5kfGmxbjDBd5NigQ>? NU\uRW5iOSCq MV7EUXNQ M1u1eWlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO|Qh|ryP MnHsNlQ6ODB{Nk[=
MCF7 NVzWN2NiTnWwY4Tpc44hSXO|YYm= M3fzUFEhcA>? MWDEUXNQ MYPJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCHNUS1T{BufXSjboStcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMTFOwG0> MmnaNlQ6ODB{Nk[=
U87MG MWXGeY5kfGmxbjDBd5NigQ>? MnvUNUBp M{XJdmROW09? NHrpTJlKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDFR|UxKG:oIECuNVMh|ryP NF61ZnQzPDlyMEK2Oi=>
A2780 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWq3NkBp NXvBS3h4TE2VTx?= MXnFR|UxRTBwNUKg{txO M1X3ZlI1QTByMk[2
SKMES-1 M3j0bmN6fG:2b4jpZ{BCe3OjeR?= NEizSlgyKM7:TR?= MWS3NkBp M2G1NWlv\HWlZYOgZ4VtdCCmZXH0bC=> NXXjPJY5OjZyMUOzNVg>
H596 M{f3c2Z2dmO2aX;uJGF{e2G7 NGDlVWIyKM7:TR?= MoDHTY1x[Wm{czDj[YxtKG2rZ4LheIlwdg>? NF72S3czPjBzM{OxPC=>
HCC2450 M1Tyb2Z2dmO2aX;uJGF{e2G7 NEGwTHUyKM7:TR?= NVTPW4RIUW2yYXnyd{Bk\WyuIHnueoF{cW:w M{D0O|I3ODF|M{G4
A549 NYDhSVluTnWwY4Tpc44hSXO|YYm= MnfLOVAxKG6P NYLLOZl2PDhiaB?= NF3he|hFVVOR NGDoVoxKdmirYnn0d{BCc3RiYXP0bZZifGmxbh?= MlPRNlU6Ozd{OUm=
A549 MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xJO69VQ>? NWn4WIF2PzJiaB?= MnvzSG1UVw>? NEnDTppKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M3jEWFI2QTN5Mkm5
H522 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPlPVQyKM7:TR?= MVW3NkBp MVjEUXNQ NVPldJlYUW6qaXLpeJMh[2WubDDndo94fGh? NGnneWQzPTl|N{K5PS=>
LNCaP M2DNOGZ2dmO2aX;uJGF{e2G7 M2jRWlEh|ryP MnvmV5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN? MnrpNlU{PjB5OUm=
LNCaP95 NWXwOYpnTnWwY4Tpc44hSXO|YYm= MWixJO69VQ>? MYrTeZBxemW|c3XzJJAuSUuWIHzleoVtew>? M2XBNlI2OzZyN{m5
HCT-15 NFT0XWxCeG:2b4Ppd{BCe3OjeR?= M1\BbFExKM7:TR?= NFTMTJY1QCCq M3f5WGROW09? NFvlZYZKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVUh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= NU\rRXFKOjVzNUKyOFU>
HCT-116 NGLMe5RCeG:2b4Ppd{BCe3OjeR?= MoXzNVAh|ryP MX:0PEBp M1fDcGROW09? M334[Wlv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xNVYh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M1XLRVI2OTV{MkS1
NCI-H460 MknxRZBwfG:|aYOgRZN{[Xl? MoKxNVAh|ryP Mli5OFghcA>? NWW2NGh7TE2VTx?= MmS3TY5lfWOnczDhdI9xfG:|aYOgbY4hVkOLLVi0OlAh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MmrqNlUyPTJ{NEW=
SKOV-3 NGLuU2hCeG:2b4Ppd{BCe3OjeR?= MkT6NVAh|ryP NEO3cXI1QCCq MX3EUXNQ M3f6Z2lv\HWlZYOgZZBweHSxc3nzJIlvKFONT2[tN{Bk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w MXGyOVE2OjJ2NR?=
BSY-1 NUjHVllUSXCxdH;zbZMhSXO|YYm= NXzSO5hWOTBizszN MWO0PEBp M1j4SmROW09? NYG4WGJRUW6mdXPld{BieG:ydH;zbZMhcW5iQmPZMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= NFTtV4szPTF3MkK0OS=>
MKN-1 Mlz1RZBwfG:|aYOgRZN{[Xl? MV:xNEDPxE1? MXu0PEBp NEXMeIlFVVOR Ml7ZTY5lfWOnczDhdI9xfG:|aYOgbY4hVUuQLUGgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? Mk[zNlUyPTJ{NEW=
NCI-H522 NWnSR5J3SXCxdH;zbZMhSXO|YYm= MXixNEDPxE1? M2qydFQ5KGh? NEHa[|JFVVOR M{jVS2lv\HWlZYOgZZBweHSxc3nz NGrjPFIzPTF3MkK0OS=>
OVCAR-3 MofURZBwfG:|aYOgRZN{[Xl? MojqNVAh|ryP MkHkOFghcA>? Mn\nSG1UVw>? MnzCTY5lfWOnczDhdI9xfG:|aYO= NIjJUGwzPTF3MkK0OS=>
HBC-5 NI\FWIJCeG:2b4Ppd{BCe3OjeR?= MUmxNEDPxE1? NYD1VIxvPDhiaB?= NHG5fplFVVOR NHm3[HlKdmS3Y3XzJIFxd3C2b4Ppdy=> MoTZNlUyPTJ{NEW=
RXF-631L NV;xToE2SXCxdH;zbZMhSXO|YYm= MWOxNEDPxE1? NV;jdHp4PDhiaB?= MVTEUXNQ M4nSSmlv\HWlZYOgZZBweHSxc3nz MWqyOVE2OjJ2NR?=
MKN-45 M{XiOmFxd3Sxc3nzJGF{e2G7 NFjW[3oyOCEQvF2= MXm0PEBp MXrEUXNQ MmfpTY5lfWOnczDhdI9xfG:|aYO= NGfSUJEzPTF3MkK0OS=>
BON-1 M37rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPrfYdbPTByIH7N NVfGOpUxOTBiZB?= NF:zW4xFVVOR NUWwSJREUW6qaXLpeJMh[2WubDDndo94fGh? NYPmNJFGOjVyMk[yPVI>
BON-1 M2[0fGZ2dmO2aX;uJGF{e2G7 NVjxNYlWPTByIH7N M1PwdFQhcA>? NYjqVGFMTE2VTx?= MVfJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGTodlMxQCCjbnSgV4VzPDd| MlHpNlUxOjZ{OUK=
QGP-1 MYXGeY5kfGmxbjDBd5NigQ>? MlrMOVAxKG6P MVS0JIg> MmfsSG1UVw>? NEmyRllKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez NGPiPIMzPTB{NkK5Ni=>
Huh7 NXSyZWNXTnWwY4Tpc44hSXO|YYm= Mn;INUDPxE1? MUGxJIg> NH\WUJNFVVOR NUPHZ454UW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBU\XJ2N{S= MlHlNlUxODR2MEO=
BNL M3nDUGZ2dmO2aX;uJGF{e2G7 MnvRNUDPxE1? NVfvV2pQOSCq NFX3VYtFVVOR MYjJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gV|Y> NGPqepczPTByNESwNy=>
MDA-MB-175 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm5NpJOOSEQvF2= M{Xlc|Uh\A>? NXnE[GN3TE2VTx?= MXrJR|UxRDFizszN M13OTlI1QDd7N{m2
MDA-MB-134 NUjxNJFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyzTGQyKM7:TR?= MVG1JIQ> MUTEUXNQ NIf3bIlKSzVyPEGg{txO MnP3NlQ5Pzl5OU[=
HCC1500 M2j5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTz[YFHOSEQvF2= NFvCUFA2KGR? MWHEUXNQ NEOyVINKSzVyPEGg{txO NWPLWGpqOjR6N{m3PVY>
EFM-19 Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXRRYVJOSEQvF2= NVnMS2NXPSCm NXnRSJN2TE2VTx?= MnS2TWM2ODxzIN88US=> NGT1R|EzPDh5OUe5Oi=>
ZR-75-30 NFHvb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OxO|Eh|ryP NVSzVWVTPSCm MnjBSG1UVw>? M2LjcGlEPTB:MTFOwG0> M4S3bVI1QDd7N{m2
MDA-MB-361 NVTITnZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxJO69VQ>? NYjJNHg4PSCm NHfF[XlFVVOR M2faXmlEPTB:MTFOwG0> MnzMNlQ5Pzl5OU[=
T-47D MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOxJO69VQ>? MoLWOUBl NWjub5Y2TE2VTx?= NFTiNHlKSzVyPEGg{txO MlvWNlQ5Pzl5OU[=
SK-BR-3 NFv1S2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWixJO69VQ>? Mn3zOUBl MWTEUXNQ NYDBXnpmUUN3MEyxJO69VQ>? MV:yOFg4QTd7Nh?=
UACC-732 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofYNUDPxE1? MmDrOUBl NEHEOWVFVVOR NYHOU4ZRUUN3MEyxJO69VQ>? MkTTNlQ5Pzl5OU[=
BT-474 NGHnd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\pUY8yKM7:TR?= NHHOcFU2KGR? M1jpPWROW09? M2rLUGlEPTB:MTFOwG0> M2\JblI1QDd7N{m2
HCC202 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL3eWdZOSEQvF2= M376PVUh\A>? MoPhSG1UVw>? M3vDe2lEPTB:MTFOwG0> MlXHNlQ5Pzl5OU[=
MCF7 NX3yd3NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCxJO69VQ>? M4f3bFUh\A>? NYXlNWJ[TE2VTx?= MYHJR|UxRDFizszN NYX5cZE6OjR6N{m3PVY>
MDA-MB-415 NGC4SYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLPNUDPxE1? M2PRdVUh\A>? NUK0OHBLTE2VTx?= NX\ROYJFUUN3MEyxJO69VQ>? MnvLNlQ5Pzl5OU[=
MDA-MB-453 NWm5fFlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3ad24yKM7:TR?= NX;5[GRUPSCm M1LnZmROW09? NFj1Z4RKSzVyPEGg{txO M2jxRVI1QDd7N{m2
ZR-75-1 M2HXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX2NUDPxE1? MUi1JIQ> M4HQbGROW09? M13TXWlEPTB:MTFOwG0> M1j4[VI1QDd7N{m2
HCC38 NUjrbJZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOxJO69VQ>? NV3lT4JUPSCm MX3EUXNQ MoW3TWM2ODxzIN88US=> NVzsXGN{OjR6N{m3PVY>
HCC1419 NWLFcmlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe1bXB2OSEQvF2= MorOOUBl MVHEUXNQ Mnz3TWM2ODxzIN88US=> M4LrfFI1QDd7N{m2
UACC-812 M2S5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGxJO69VQ>? MXu1JIQ> MYDEUXNQ Ml;1TWM2ODxzIN88US=> MmjVNlQ5Pzl5OU[=
HCC1187 Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPFNUDPxE1? MXu1JIQ> MnfQSG1UVw>? NHjzbotKSzVyPEGg{txO NVfRVJR{OjR6N{m3PVY>
KPL-1 NFHuXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfiNUDPxE1? NYCzbmF2PSCm NYLFUoRCTE2VTx?= NUjES2FoUUN3MEyxJO69VQ>? MnLzNlQ5Pzl5OU[=
SUM-225 M3PMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXyxJO69VQ>? Mnn5OUBl Mmm1SG1UVw>? MVrJR|UxRDFizszN MWWyOFg4QTd7Nh?=
EFM-192A MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYexJO69VQ>? M2Thc|Uh\A>? M1TOV2ROW09? M3qwbGlEPTB:MTFOwG0> M3v4PVI1QDd7N{m2
JIMT-1 M2rrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYexJO69VQ>? MWG1JIQ> MWDEUXNQ NX6xTWw{UUN3MEyxJO69VQ>? M2HE[FI1QDd7N{m2
HCC1143 M1PzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLVXVcyKM7:TR?= NHS4cHc2KGR? NEjvT3pFVVOR NIHBVIFKSzVyPEGg{txO NHW1TYszPDh5OUe5Oi=>
HCC2218 M4jQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnYZZlrOSEQvF2= NHjLco02KGR? MkK2SG1UVw>? MVTJR|UxRDFizszN MkXiNlQ5Pzl5OU[=
MDA-MB-468 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LBNlEh|ryP MWW1JIQ> MlnmSG1UVw>? M2PQb2lEPTB:MTFOwG0> NITqN3MzPDh5OUe5Oi=>
BT-20 M1XRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e0OVEh|ryP MX[1JIQ> MkfKSG1UVw>? M1;1NWlEPTB:MTFOwG0> NGnIUGYzPDh5OUe5Oi=>
MDA-MB-435 NIr6elJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\MN|Eh|ryP MVi1JIQ> Mm\FSG1UVw>? NUHNdmdnUUN3MEyxJO69VQ>? M2nVNVI1QDd7N{m2
BT-549 NFjXe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XrSlEh|ryP NHfJWIs2KGR? NH;DOphFVVOR NVfKVpNZUUN3MEyxJO69VQ>? NGH0OJgzPDh5OUe5Oi=>
HCC1806 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n1V|Eh|ryP M2e0blUh\A>? NY\FbINsTE2VTx?= MVnJR|UxRDFizszN NFGyNIkzPDh5OUe5Oi=>
HCC1937 M3vDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfnNUDPxE1? NWn6Z4t[PSCm MXjEUXNQ M1vMTWlEPTB:MTFOwG0> MkLkNlQ5Pzl5OU[=
Hs578T M4nJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO3fmNEOSEQvF2= NH65d2M2KGR? MkL5SG1UVw>? MVjJR|UxRDFizszN NWXySY9sOjR6N{m3PVY>
LN18 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPaPWgzOCEQvF2= NFuwS4k4OiCq NVHLdHd1TE2VTx?= MVjJR|UxRDVizszN NEG3eVEzPDd2MUC3OC=>
LN229 NYPpN3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml23NlAh|ryP NX7zcGtIPzJiaB?= MoezSG1UVw>? Mnu0TWM2ODx3IN88US=> NH61fHkzPDd2MUC3OC=>
LNZ308 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TjO|IxKM7:TR?= MnPxO|IhcA>? NUXmZYlbTE2VTx?= NH\sVJNKSzVyPEWg{txO NU[zcW1LOjR5NEGwO|Q>
T98G MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKyNEDPxE1? NGn1XG04OiCq MmSySG1UVw>? MXjJR|UxRDVizszN NED5PHQzPDd2MUC3OC=>
U87 M3fZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO1[VV2OjBizszN MXu3NkBp NUHG[INKTE2VTx?= NHzSclZKSzVyPEWg{txO M3;SW|I1PzRzMEe0
LN18 MVXGeY5kfGmxbjDBd5NigQ>? MVu1JO69VQ>? NV3rUVJ3OjRiaB?= MXnEUXNQ MXzJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtV NETZbYwzPDd2MUC3OC=>
LNZ308 NGPY[nhHfW6ldHnvckBCe3OjeR?= NGS5TIw2KM7:TR?= MVqyOEBp MWnEUXNQ M{jkd2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R? MViyOFc1OTB5NB?=
Saos-2 NI\iUXBHfW6ldHnvckBCe3OjeR?= M2PYb|UxKM7:TR?= MWC0PEBp MmHXTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? NIH4TZgzPDd{N{[2NC=>
MG-63 NV\Ld2lXTnWwY4Tpc44hSXO|YYm= MXe1NEDPxE1? M2j1PVQ5KGh? M1H6XmlvcGmkaYTzJINmdGxiaX72ZZNqd25? NVjxenJ[OjR5Mke2OlA>
SJSA-1 NV[wWW1JTnWwY4Tpc44hSXO|YYm= NGjJXm02OCEQvF2= M4\3fVQ5KGh? NGPFVlNKdmirYnn0d{Bk\WyuIHnueoF{cW:w M3:4bFI1PzJ5Nk[w
Saos-2 MnnkSpVv[3Srb36gRZN{[Xl? M2PwZVUxKM7:TR?= M4W2bVQ5KGh? MkT5TY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW|c3nvci=> MVuyOFczPzZ4MB?=
MG-63 NEO4eGRHfW6ldHnvckBCe3OjeR?= NGnhXFk2OCEQvF2= M4TXU|Q5KGh? M{i2TGlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> MVeyOFczPzZ4MB?=
SJSA-1 Mn22SpVv[3Srb36gRZN{[Xl? MWW1NEDPxE1? M1O1ZlQ5KGh? M1rMeWlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> NECzOnczPDd{N{[2NC=>
Saos-2 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fvb|UxKM7:TR?= M4XrcFQ5KGh? M1T4OGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NIHPVGIzPDd{N{[2NC=>
MG-63 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HlbVUxKM7:TR?= MmjGOFghcA>? NVPSVZhuUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= M{fTeVI1PzJ5Nk[w
SJSA-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjGToQ2OCEQvF2= MW[0PEBp NXzDTmpiUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NULMUHhxOjR5Mke2OlA>
FaDu M3jzdmZ2dmO2aX;uJGF{e2G7 NE\Bdnk2KM7:TR?= MVeyOEBp MWnEUXNQ Mm\RVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= MlHpNlQ3OzFzNEe=
EMT6 M1myTmZ2dmO2aX;uJGF{e2G7 NYjqUJo1PSEQvF2= NW\MfHdZOjRiaB?= NFeyS4lFVVOR MnO1VoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= M37SOlI1PjNzMUS3
HCT116 MVLGeY5kfGmxbjDBd5NigQ>? NEjmVFY2KM7:TR?= NWHzVY1sOjRiaB?= NIS3dmNFVVOR NEW3O5NT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> M2D3XFI1PjNzMUS3
U87 MUTGeY5kfGmxbjDBd5NigQ>? NVPwXWVKPSEQvF2= M33MUVI1KGh? MXnEUXNQ MX3S[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= MXeyOFY{OTF2Nx?=
GBM NYH0XI5ISXCxcITvd4l{KEG|c3H5 M4rySlLPxE1? M4C2blQ5cA>? MY\EUXNQ NX\aflU4cW6mdXPl[EBpcWeqZYKgcIV3\Wy|IH;mJIFxd3C2b4Ppd{wh[W6mIHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gQ>? MV[yOFUxODR7Mh?=
BON NUXRZ2g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi5bmYyNTYQvF2= MX[3Nog> NUn0OVlj\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? NIHRR4YzPDR2M{WyNy=>
BON MYHBdI9xfG:|aYOgRZN{[Xl? MX:xMVXPxE1? MljDNlRp MUTpcoNz\WG|ZYOgZZBweHSxc3nz NUXBRYIzOjR2NEO1NlM>
H1975 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqwMlMuQS54zszN NVm0[nd6PzKq NXnxTpZkTE2VTx?= M1ziT2lEPTB;MT6zPFXPxE1? MXKyOFM{Pzh2Nh?=
H1975 M1u2UWFxd3C2b4Ppd{BCe3OjeR?= NYOzRlk{Os7:TR?= M2rySlI1cA>? M{njTWROW09? NUjLW3VqcW6lcnXhd4V{KGGyb4D0c5NqeyC{YYTlJJNq\26rZnnjZY51dHl? NFLaU2MzPDN|N{i0Oi=>
T-ALL NFy2U5hCeG:ydH;zbZMhSXO|YYm= MoK4ZoV1f2WnbjCxMlQh[W6mIEWuN{BuVSCjdDCyOIgh[W6mIECuPUBidmRiNT61JI1OKGG2IES4bEBqdiCmaX\m[ZJmdnRiY3XscEBtcW6n MYKyOEBweiB2OHi= NUnMcWt5TE2VTx?= M2fkUoFn\mWldIOgeIhmKFCLM1ugdIF1cHejeTDpckBVNUGOTDDj[YxtKGyrbnXz M4nke|I1OzFyN{O2
BCR-ABL M3;GR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnxWVhOOC5{NT2xNO69VQ>? MlfUOIQ> Mnu5d4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>? M{LOSlI1OjR2NkGy
LC-1/SQSF M{DLeGZ2dmO2aX;uJGF{e2G7 MlPMN:69VQ>? MkXMNlRp M3;yT2ROW09? NVrJPJVT\GWlcnXhd4UhVlKIMjDwdo91\WmwIHzleoVt NUjo[4x[OjN7OECwPVM>
Primary CLL cells NYHDbmUzSXCxcITvd4l{KEG|c3H5 NFzpOY8yNTFyzszN MUi0PIg> MUfpcoR2[2W|IHHwc5B1d3OrczDpckBEVExiY3XscJMhcW6mZYDlcoRmdnRib3[gdJJw\26xc4TpZ{Bu[XKtZYLz MXiyN|g2ODhyNx?=
Primary CLL cells NF;JbXdMcW6jc3WgRZN{[Xl? M2TKW|LPxE1? MUGzNI1qdg>? NVzWNWRC\GWlcnXhd4VlKFCLM1ugZYN1cX[rdIm= MWGyN|g2ODhyNx?=
Primary CLL cells MYTDfZRwfG:6aXOgRZN{[Xl? MV[y{txO NEDibHozPGh? NF;ZZ5FqdmS3Y3XzJINmdGxiY4n0c5RwgGmlaYT5 NEf4NI0zOzh3MEiwOy=>
human NSCLC cell lines M1rCZWFxd3C2b4Ppd{BCe3OjeR?= MX[wMlEzPS12zszN NGXBXIozPGh? NWLkSFZLTE2VTx?= MlPwTWM2OHNicnHu[4V{KG[{b32gNE41NTMQvF2= M1LCZlI{PTZ{NEey
human HCC cell lines MmDWR4VtdCC4aXHibYxqfHliYYPzZZk> Mn7QNE4xODVvMd88US=> MXK0PIg> NVy5NW1YUUN3ME2x{txO Mn7NNlM1QDl7OUm=
Huh7 M3vZNWtqdmG|ZTDBd5NigQ>? MWmx{txO NFjnPXo1QGh? NVXLSnlKe2mpbnpvsKFk[W62bImgdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gRYt1 MWeyN|Q5QTl7OR?=
SK-HEP1 M1e3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\OR|EuOjEQvF2= NXTjUIJ5PzKq M4rrR2ROW09? NIOz[ZdKSzVy78{cNe69VQ>? M2DZUVI{PDd7MUO2
786-0 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7BNU0zOM7:TR?= NFrYR204Omh? MXfEUXNQ MXzJR|Ux97zeMd88US=> NGHZV|kzOzR5OUGzOi=>
JVM2 MVrDfZRwfG:6aXPpeJkh[XO|YYm= MnXkNE4zNTJyzszN NYPYflFZPzKq NEfQN2NFVVOR MWjJR|UxRTBwOd88US=> Mlz5NlMzOzh4M{m=
EHEB MnXRR5l1d3SxeHnjbZR6KGG|c3H5 NXLsTZhzOC5{LUKw{txO MXK3Nog> MXrEUXNQ MWfJR|UxRTBwN988US=> MXmyN|I{QDZ|OR?=
MEC2 M1Tr[GN6fG:2b4jpZ4l1gSCjc4PhfS=> M{[ycVAvOi1{MN88US=> MlT5O|Jp M2LjN2ROW09? MoPxTWM2OD1yLkhOwG0> NWm2PZhiOjN{M{i2N|k>
primary B-CLL lymphocytes NHL6T5hCeG:ydH;zbZMhSXO|YYm= M2jlT2lEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? NHuwe|czPGh? M{\nbWROW09? NF65RXNKSzVy78{cN:69VSCob4KgZYxtKHCjdHnlcpR{ M4PreFI{OjN6NkO5
primary B-CLL lymphocytes NETBNHJMcW6jc3WgRZN{[Xl? M3zoXGlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? NHvGWFUzPGh? M{TubIlvcGmkaYTzJJA4OFN4SzCmJFRGNUKSMTDlfJBz\XO|aX;u MnjrNlMzOzh4M{m=
human NSCLC NHLUW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX5RmJrOC53LUNOwG0> NHi4cIQ4Omh? MoDDTWM2OD1zzszN MlHvNlI4QDF|OUO=
human NSCLC MWnLbY5ie2ViQYPzZZk> M4e4VlHPxE1? MkjQNlRp NEK1[5pqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70 MlTpNlI4QDF|OUO=
Y1 cell line NWHwUpc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6wMlHPxE1xMd88US=> MWWyOIg> MmLvSG1UVw>? NH;aVHFqdmirYnn0d{A3OO,:hTDj[YxtKH[rYXLpcIl1gSCrbjDNfYMuW2O2cj30doFve2[nY4Tl[EBk\Wyucx?= MnXrNlI3QTJ7MES=
PIK3CA-mutant MCF7 NFOwe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfHTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO|NvVQ>? M33XSVczcA>? NY\P[GhxT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= NF\jVngzOjZ3M{m2Oy=>
PIK3CA-mutant MCF7 NHjPO4ZMcW6jc3WgRZN{[Xl? M3fwUWlEPTB;MUG0xtE{dk1? MmnhO|Jp M3POU2lEPTB;MUG0xtE{dk1iaX6gdoVlfWOrbnegRYt1KHCqb4PwbI9zgWyjdHnvckBt\X[nbIO= MWKyNlY2Ozl4Nx?=
MCF7-myr-Akt NFnlOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jFfmdKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P M2WxSVczcA>? NEHpbXdIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?= MYqyNlY2Ozl4Nx?=
colon cancer cell lines MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\hbFAuOTEQvF2= NX\u[XMxPzKq NVfwWpp6TE2VTx?= MXLJR|UxRTIQvF2= NEL5cJgzOjV2M{i1Oy=>
gastric cancer cell lines MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfIOpp[OC1zMN88US=> NUPmcHFCPzKq Mor6SG1UVw>? M3\LeGlEPTB;Mj21{txO MnHNNlI2PDN6NUe=
HCT-116/HT-29/MKN-45 NF;K[m9CeG:ydH;zbZMhSXO|YYm= NVnld5E1Os7:TR?= M3HIVVQ5cA>? M1H2fZNpcW[2IHnuJGczKHCqYYPl M2X5VVIzPTR|OEW3
HT-29 and HCT-116 NWjEZ4g2S2G|cHHz[UBie3OjeR?= NFvOTpo2|ryP MVSyOIg> MX7pcoR2[2W|IHPhd5Bie2ViYXP0bZZqfHl? MlTDNlI2PDN6NUe=
MM cell lines M2Xqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[xNO69VQ>? M1z0cFI1cA>? MWPEUXNQ NV;NZnRDUUN3MDD2ZZJq\XNiYX3vcoch\GmoZnXy[Y51KGOnbHygcIlv\XNiaX6geIlu\SCjbnSg[I9{\SCmZYDlcoRmdmOn M1j2NFIzOjB5NEi1
ARP-1 MmjsRZBweHSxc3nzJGF{e2G7 NYTpbGZOOTEQvF2= MYmyOIg> M2\YfWROW09? MUPpcoR2[2W|IF3NJINmdGxiYYDvdJRwe2m|IITodo92\2hiY3HzdIF{\SCjY4TpeoF1cW:w M1ztOFIzOjB5NEi1
SNU-601 NWjC[IdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXe3Nog> NYWwRVkyTE2VTx?= NF;IRnpKSzVyPUCuPFE3yrFyLkC2N:69VQ>? NHPhZ3QzOjF3OUixOC=>
SNU-1 NVztXXpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK3U|g6PzKq M3TRR2ROW09? NVnnUXJxUUN3ME2xMlA5OsLzMD6wNljPxE1? MVmyNlE2QThzNB?=
SNU-668 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUi3Nog> M1XNXWROW09? NX;hUlRnUUN3ME2xMlU4QcLzMD6wO|TPxE1? Mk\5NlIyPTl6MUS=
AGS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfjXXdYPzKq Mn3oSG1UVw>? M1viVWlEPTB;MT63NVTDuTBwMUG3{txO M4fQTVIzOTV7OEG0
SNU-216 Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LJTVczcA>? NWDjWYxLTE2VTx?= MVTJR|UxRTJwNkmyxtExNjB6Mt88US=> Ml3mNlIyPTl6MUS=
SNU-5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnHeJE4Omh? M2HCT2ROW09? NV\zTGIyUUN3ME2xMlM2OcLzMD6wPVHPxE1? NXfPUoJ3OjJzNUm4NVQ>
SNU-638 M1LPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHuZlg4PzKq NVfFfG5qTE2VTx?= MX;JR|UxRTJwMkiyxtExNjB3M988US=> M2P5NlIzOTV7OEG0
SNU-16 NX7HWFhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjpN2M4Omh? MmjOSG1UVw>? NW\qPZNFUUN3ME2xMlU4O8LzMD6wNFHPxE1? NHnBSlIzOjF3OUixOC=>
SNU-484 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPPO|Jp M1nwV2ROW09? M2nNdmlEPTB;MT63NljDuTBwMES1{txO M1:3PVIzOTV7OEG0
SNU-620 M3\PUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUS3Nog> Mk\6SG1UVw>? NIHhS3BKSzVyPUKuPVM6yrFyLkCwNe69VQ>? Mm\4NlIyPTl6MUS=
SNU-719 Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7qeY44Omh? M1qyUGROW09? NXTNVWxKUUN3ME2zMlA{P8LzMD6wN|LPxE1? MlHoNlIyPTl6MUS=
glioma cell lines Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXJfYo4Omh? NV;LTFZDUUN3ME2xMVLPxE1? MWKyNlA3PTB6MB?=
U87 NF63SFFCeG:ydH;zbZMhSXO|YYm= Mm\aNu69VQ>? MknrO|Jp NYLkW3Q3cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDhcoQh[2ynYY\l[EBRSVKSIHHu[EBk[XOyYYPlMVM> NX:4e|E{OjJyNkWwPFA>

... Click to View More Cell Line Experimental Data

In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay:[1]
+ Expand

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:[1]
+ Expand
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Formulation: In 15% Captisol.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2
NCT01971489 Withdrawn Adult Solid Neoplasm|Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI) September 2015 Phase 1
NCT02452294 Recruiting Malignant Melanoma|Metastases University Hospital Tuebingen|University Hospital Dresden July 2015 Phase 2
NCT02303041 Completed Basal Cell Carcinoma (BCC) of the Skin|Nevoid Basal Cell Carcinoma (BCC) Syndrome|Recurrent Skin Cancer Anne Chang|National Cancer Institute (NCI)|Stanford University February 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) supplier | purchase Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) cost | Buparlisib (BKM120, NVP-BKM120) manufacturer | order Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID